364 related articles for article (PubMed ID: 19116940)
1. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH
Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.
Hinchcliff M; Huang CC; Ishida W; Fang F; Lee J; Jafari N; Wilkes M; Bhattacharyya S; Leof E; Varga J
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S86-96. PubMed ID: 22691216
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.
Daniels CE; Wilkes MC; Edens M; Kottom TJ; Murphy SJ; Limper AH; Leof EB
J Clin Invest; 2004 Nov; 114(9):1308-16. PubMed ID: 15520863
[TBL] [Abstract][Full Text] [Related]
5. Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis.
Ponsoye M; Frantz C; Ruzehaji N; Nicco C; Elhai M; Ruiz B; Cauvet A; Pezet S; Brandely ML; Batteux F; Allanore Y; Avouac J
Ann Rheum Dis; 2016 Dec; 75(12):2142-2149. PubMed ID: 26912566
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
[TBL] [Abstract][Full Text] [Related]
7. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors.
Maurer B; Distler A; Dees C; Khan K; Denton CP; Abraham D; Gay RE; Michel BA; Gay S; Hw Distler J; Distler O
Ann Rheum Dis; 2013 Dec; 72(12):2039-46. PubMed ID: 24013728
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease.
Zerr P; Distler A; Palumbo-Zerr K; Tomcik M; Vollath S; Dees C; Egberts F; Tinazzi I; Del Galdo F; Distler O; Schett G; Spriewald BM; Distler JH
Am J Pathol; 2012 Nov; 181(5):1672-80. PubMed ID: 22940072
[TBL] [Abstract][Full Text] [Related]
9. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis.
Reich N; Tomcik M; Zerr P; Lang V; Dees C; Avouac J; Palumbo K; Horn A; Akhmetshina A; Beyer C; Xie W; Bennett BL; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2012 May; 71(5):737-45. PubMed ID: 22258492
[TBL] [Abstract][Full Text] [Related]
10. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases.
Vittal R; Zhang H; Han MK; Moore BB; Horowitz JC; Thannickal VJ
J Pharmacol Exp Ther; 2007 Apr; 321(1):35-44. PubMed ID: 17218487
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate attenuates myocardial remodeling through inhibition of platelet-derived growth factor and transforming growth factor activation in a rat model of hypertension.
Jang SW; Ihm SH; Choo EH; Kim OR; Chang K; Park CS; Kim HY; Seung KB
Hypertension; 2014 Jun; 63(6):1228-34. PubMed ID: 24591339
[TBL] [Abstract][Full Text] [Related]
12. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.
Pannu J; Asano Y; Nakerakanti S; Smith E; Jablonska S; Blaszczyk M; ten Dijke P; Trojanowska M
Arthritis Rheum; 2008 Aug; 58(8):2528-37. PubMed ID: 18668566
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis.
Beyer C; Reich N; Schindler SC; Akhmetshina A; Dees C; Tomcik M; Hirth-Dietrich C; von Degenfeld G; Sandner P; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2012 Jun; 71(6):1019-26. PubMed ID: 22294631
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis.
Horn A; Kireva T; Palumbo-Zerr K; Dees C; Tomcik M; Cordazzo C; Zerr P; Akhmetshina A; Ruat M; Distler O; Beyer C; Schett G; Distler JH
Ann Rheum Dis; 2012 May; 71(5):785-9. PubMed ID: 22402139
[TBL] [Abstract][Full Text] [Related]
15. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
Beyer C; Distler JH; Distler O
Swiss Med Wkly; 2010; 140():w13050. PubMed ID: 20419513
[TBL] [Abstract][Full Text] [Related]
16. Pomalidomide is effective for prevention and treatment of experimental skin fibrosis.
Weingärtner S; Zerr P; Tomcik M; Palumbo-Zerr K; Distler A; Dees C; Beyer C; Shankar SL; Cedzik D; Schafer PH; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2012 Nov; 71(11):1895-9. PubMed ID: 22904257
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.
Iwamoto N; Distler JH; Distler O
Curr Rheumatol Rep; 2011 Feb; 13(1):21-7. PubMed ID: 21042889
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
Distler JH; Distler O
Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
[TBL] [Abstract][Full Text] [Related]
19. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.
Distler JH; Distler O
Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v10-1. PubMed ID: 18784126
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis.
Avouac J; Fürnrohr BG; Tomcik M; Palumbo K; Zerr P; Horn A; Dees C; Akhmetshina A; Beyer C; Distler O; Schett G; Allanore Y; Distler JH
Arthritis Rheum; 2011 Mar; 63(3):800-9. PubMed ID: 21360510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
